FDA approves paediatric version of ProAir RespiClick (albuterol sulfate) to treat obstructive airway disease and for prevention of exercise-induced bronchospasm- Teva

Teva announced that the FDA has approved ProAir RespiClick (albuterol sulfate) Inhalation Powder for the treatment or prevention of bronchospasm in children 4 to 11 years of age with reversible obstructive airway disease and for the prevention of exercise-induced bronchospasm (EIB).ProAir RespiClick was approved by the FDA for use in patients 12 years of age and older in March 2015 and remains the only breath-activated, multi-dose, dry powder, short-acting beta-agonist (SABA) inhaler available in the USA.

Comment: The prevalence of childhood asthma in the USA is high, at more than six million patients, and that number continues to rise. For this young population of asthma patients, learning to use inhalers properly can be quite challenging. Thus, the paediatric indication for ProAir RespiClick is important as it represents a new rescue inhaler option for younger patients that eliminates the need for hand-breath coordination during inhalation and was designed to be used without a spacer.